[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psychedelic-microdosing-effects-on-mood-cognition-subjective-well-being-and-mri\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psychedelic-microdosing-effects-on-mood-cognition-subjective-well-being-and-mri":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100627493",false,"NCT07449351","Psilocybin Microdosing on Cognition, Mood and Quality of Life","Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study","Inclusion Criteria:\n\n* No history of psychedelic use\n* Able to read, speak, and understand English\n* Able and willing to provide written informed consent, and willing to commit to study protocol\n* Women of childbearing potential must be on a highly effective birth control method\n\nExclusion Criteria:\n\n* Positive screen for recreational drugs or alcohol on test day will result in rescheduling the appointment\n* Current mood, developmental, or psychotic disorders (e.g., schizophrenia, affective disorders) per DSM-V\n* Current or past alcohol or substance use disorder per DSM-V\n* IQ \\\u003C70 on the Weschler Abbreviated Scale of Intelligence\n* Serious medical, neuro-ophthalmological, or neurological illness (e.g., cancer, seizure disorders, encephalopathy)\n* Current pregnancy, breastfeeding, or ineffective birth control methods\n* History of head trauma with loss of consciousness lasting \\>30 minutes or concussion in last 30 days\n* Any medical\u002Fneurological condition that could compromise neurocognitive performance (e.g., epilepsy, multiple sclerosis, fetal alcohol syndrome)\n* Anyone deemed unsafe to study personnel for any reason; e.g., suicidal ideation\n* Focal brain lesion seen on structural MRI\n* MRI contraindications (e.g., implanted metallic object, severe claustrophobia)",true,"ALL","21 Years","40 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural\u002Ffunctional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.",[27],"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI",[29,30,31,32,33],"Psychedelics","Psilocybin","MRI","fMRI","Microdosing","NOT_YET_RECRUITING","2026-06-19",{"date":37,"type":38},"2026-06-23","ACTUAL",{"date":40,"type":21},"2026-08-10",{"date":42,"type":21},"2028-04-01",{"name":44,"class":45},"Yale University","OTHER",""]